A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
pharmaand GmbH
With
Foundation Medicine
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Be 18 years old at the time the informed consent is signed
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic
Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
Be eligible for treatment with physician's choice of comparator treatment (abiraterone acetate, enzalutamide or docetaxel)
Experienced disease progression after having received 1 prior next generation androgen receptor-targeted therapy
Have a deleterious mutation in a BRCA1/2 or ATM gene
You may not be if
Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
Prior treatment with any PARP inhibitor
Prior treatment with chemotherapy for metastatic castration-resistant prostate cancer
Symptomatic and/or untreated central nervous system metastases
Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug
Clareo Health | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
